Last reviewed · How we verify

TachoSil

GATT Technologies BV · FDA-approved active Small molecule

TachoSil is a hemostatic agent that combines fibrin glue with collagen to promote rapid blood clotting and wound sealing.

TachoSil is a hemostatic agent that combines fibrin glue with collagen to promote rapid blood clotting and wound sealing. Used for Hemostasis support in cardiovascular surgery, Hemostasis support in general surgery, Hemostasis support in orthopedic surgery.

At a glance

Generic nameTachoSil
Also known asTachosil®, TachoSil is a sponge sealant patch that is coated with the active substances human fibrinogen and human thrombin., NCT01192022, fibrin sealant matrix, EU/1/04/277/001
SponsorGATT Technologies BV
Drug classHemostatic agent / Fibrin sealant
TargetFibrinogen (conversion to fibrin via thrombin)
ModalitySmall molecule
Therapeutic areaSurgery / Hemostasis
PhaseFDA-approved

Mechanism of action

TachoSil consists of a collagen patch coated with human fibrinogen and thrombin. When applied to a bleeding surface, the thrombin activates fibrinogen to form fibrin clots, while the collagen provides structural support. This combination creates a stable hemostatic seal that promotes tissue adhesion and accelerates hemostasis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: